GL1X · GenesisL1 explorer

MolNFT v1 · #122653 · protein

Crystal structure of HIV protease complexed with [(1S)-1-[(S)-(4- chlorophenyl)-(3,5-DIFLUOROPHENYL)METHYL]-2-[[5-fluoro-4-[2-[(2R,5S)- 5-(2,2,2-TRIFLUOROETHYLCARBAMOYLOXYMETHYL)MORPHOLIN-4-ium-2- YL]ETHYL]PYRIDIN-1-ium-3-YL]AMINO]-2-oxo-ETHYL]AMMONIUM

5IVT: “Crystal structure of HIV protease complexed with [(1S)-1-[(S)-(4…”. X-ray diffraction, 2 ligands (6EE, CL), 1 pocket (best druggability 0.71). MolNFT v1 #122653 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
5IVT
Type
protein
Length
198 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Protease
UniProt
C8B467
Ligands
6EE, CL
Pockets
1 · best druggability 0.71

Structure

x-ray diffraction · 1 distinct chain · 7% helix, 55% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BProteaseprotein997% helix, 55% strandC8B467

Ligands and binding sites

  • 6EE · (betaS)-4-chloro-beta-(3,5-difluorophenyl)-N-(5-fluoro-4-{2-[(2R,5S)-5-({[(2,2,2-trifluoroethyl)carbamoyl]oxy}methyl)morpholin-2-yl]ethyl}pyridin-3-yl)-L-phenylalaninamide · ligand · 2 copies · chains A, B
  • CL · Chloride ion · ion · 2 copies · chains A, B
  • ACT · Acetate ion · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13260.710.8435ACT, 6EE

Interfaces

1 interface between chains.

  • A–B · 1865 Ų buried · 38 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 5IVT · Crystal Structure of HIV Protease complexed with… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.